Department of Cardiology, Isala Hospital, dr. van Heesweg 2, 8025 AB Zwolle, The Netherlands.
Ambulancedienst IJsselland, Voltastraat 3-A, 8013 PM Zwolle, The Netherlands.
Eur Heart J Cardiovasc Pharmacother. 2022 Jan 5;8(1):4-12. doi: 10.1093/ehjcvp/pvaa095.
Platelet inhibition induced by P2Y12 receptor antagonists in patients with ST-elevation myocardial infarction (STEMI) can be affected by concomitant use of opioids. The aim of this trial was to examine the effect of intravenous (iv) acetaminophen compared with iv fentanyl on P2Y12 receptor inhibition in patients with STEMI.
The Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial randomized 195 STEMI patients who were scheduled to undergo primary percutaneous coronary intervention (PCI) and were pre-treated with crushed ticagrelor to iv acetaminophen (N = 98) or iv fentanyl (N = 97) in the ambulance. The primary endpoint, consisting of the level of platelet reactivity units (PRU) measured immediately after primary PCI, was not significantly different between the study arms [median PRU 104 (IQR 37-215) vs. 175 (63-228), P = 0.18]. However, systemic levels of ticagrelor were significantly higher in the acetaminophen arm at the start of primary PCI [151 ng/mL (32-509) vs. 60 ng/mL (13-206), P = 0.007], immediately after primary PCI [326 ng/mL (94-791) vs. 115 ng/mL (38-326), P = 0.002], and at 1 h after primary PCI [488 ng/mL (281-974) vs. 372 ng/mL (95-635), P = 0.002]. Acetaminophen resulted in the same extent of pain relief when compared with fentanyl [reduction of 3 points on 10-step-pain scale before primary PCI (IQR 1-5)] in both study arms (P = 0.67) and immediately after PCI [reduction of 5 points (3-7); P = 0.96].
The iv acetaminophen in comparison with iv fentanyl was not associated with significantly lower platelet reactivity in STEMI patients but resulted in significantly higher ticagrelor plasma levels and was effective in pain relief.
P2Y12 受体拮抗剂在 ST 段抬高型心肌梗死(STEMI)患者中诱导的血小板抑制作用可能受到同时使用阿片类药物的影响。本试验的目的是研究静脉注射(IV)对乙酰氨基酚与 IV 芬太尼对 STEMI 患者 P2Y12 受体抑制的影响。
阿片类药物和粉碎替格瑞洛在心肌梗死评估(ON-TIME 3)试验中,将 195 名计划接受经皮冠状动脉介入治疗(PCI)的 STEMI 患者随机分为两组,在救护车中预先给予粉碎替格瑞洛,一组给予 IV 对乙酰氨基酚(n=98),另一组给予 IV 芬太尼(n=97)。主要终点是直接PCI 后即刻测量的血小板反应单位(PRU)水平,两组间无显著差异[中位数 PRU 为 104(IQR 37-215)vs. 175(63-228),P=0.18]。然而,在直接 PCI 开始时,对乙酰氨基酚组的替格瑞洛系统水平明显更高[151ng/ml(32-509)vs. 60ng/ml(13-206),P=0.007],直接 PCI 后即刻[326ng/ml(94-791)vs. 115ng/ml(38-326),P=0.002],以及直接 PCI 后 1 小时[488ng/ml(281-974)vs. 372ng/ml(95-635),P=0.002]。与芬太尼相比,对乙酰氨基酚在减轻疼痛方面同样有效[直接 PCI 前 10 分制疼痛量表降低 3 分(IQR 1-5),两组间差异无统计学意义(P=0.67)],并且直接 PCI 后即刻[降低 5 分(3-7);P=0.96]。
与 IV 芬太尼相比,IV 对乙酰氨基酚在 STEMI 患者中并未显著降低血小板反应性,但导致替格瑞洛血浆水平显著升高,并有效缓解疼痛。